Hot Selling Best Price Nootropics Dihexa cas1401708-83-5 1g/ vial or mg/vial Raw powder hot
TDS 166 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
guangzhou
ZWXS
5mg,10mg/vial; 10vials/box
2026-12-31
peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
CertificatesBasic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptides
-
Location:
No. 41-9, Fenghuangshan Road, Beiyuan Street, Tianqiao District, Jinan City, Shandong Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History166 Inquiries
Country Product Purchase Quantity Date Posted
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
Dihexa 1401708-83-5
1 G Mar 8, 2026
Bulgaria
Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5
10 G May 27, 2025
United States
Dihexa
500 G Aug 19, 2026
United States
Dihexa
25 G Jan 26, 2025
Russia
DIHEXA
50.00 G Aug 14, 2024
United States
Dihexa
1 G Aug 22, 2026
United States
Dihexa
1 G Aug 4, 2026
United States
Dihexa
1 G Jul 30, 2026
United States
Dihexa
1 G Jul 8, 2026
United States
Dihexa
10 MG Jul 6, 2026
Australia
Dihexa
1 G Jun 30, 2026
United States
Dihexa Peptide Nootropic Neurotrophy Dihexa Powder (Pharmaceutical Grade)
1.0 G Jun 5, 2026
United States
Dihexa
1 MT May 9, 2026
United States
dihexa
1 KG May 8, 2026
Canada
Dihexa
3 G May 7, 2026
United States
Dihexa
123456 G May 4, 2026
United States
Dihexa
50 MT May 2, 2026
Canada
Dihexa
8 Apr 21, 2026
Ecuador
dihexa
1 KG Apr 20, 2026 Post an enquiry for this product
